检索结果-南通市图书馆

Expression of Human Interferon α 2b Gene in Ginseng Cells

Chemical Research in Chinese Universities 2010年第3期26卷 420-426页

作者： REN Qi WANG Chun-yi SONG Zhi-ming LIU Dan YU Hai-peng SHENG Jun co.lege of Life Science Jilin University Changchun 130012 P. R. China Changchun Institute of Biological Products Changchun 130062 P R. China liaoning yisheng biopharmaceutical co. Ltd. Shengyang 110131 P. R. China First Affiliated Hospital Jilin University Changchun 130031 P R. China Yunnan Agricultural University Kunming 650201 P.. R. China

The human interferon α 2b（hIFN-α2b） gene was cloned into binary vector pBI121 to obtain plant expression vector pBIFN. The reco.binant plasmid pBIFN was transferred into Agrobacterium tumefaciens strain LBA4404. Then the hIFN-α2b gene was introduced into ginseng callus cells via Agrobacterium-mediated transformation and the ginseng cell line carrying hIFN-α2b gene was selected on G418-co.taining medium. The presence of target gene in transformed cells was co.firmed by PCR and RT-PCR. The results indicate that hIFN-α2b gene has been integrated into the ginseng cells＇ genome, with transcription products, hIFN-α2b expressed by the transgenic ginseng cells was detected by Western blot. It was shown that a specific protein band at 19000 co.ld be observed. Cytopathic effect（CPE） inhibition assay using the W1SH-VSV system shows that the mean antiviral activity of expressed hlFN-a2α was 6.0× 10^4 IU/mL.

关键词： Human interferon × 2b Ginseng cell Plant transformation Agrobacterium tumefaciens

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in co.on cancer by single-cell transcriptomics

引用

Acta Pharmaceutica Sinica B 2022年第1期12卷 149-166页

作者： Jian Gao Zhigui Wu Mingxia Zhao Rui Zhang Manru Li Dongdong Sun Haibo Cheng Xianjia Qi Yuxian Shen Qiang Xu Hongqi Chen Dijun Chen Yang Sun State Key Laboratory of Pharmaceutical Biotechnology Chemistry and Biomedicine Innovation Center(Chem BIC)School of Life SciencesNanjing UniversityNanjin 210023China biopharmaceutical Research Institute School of Basic Medical SciencesAnhui Medical UniversityHefei 230032China Department of co.orectal Surgery Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital&InstituteShenyang 110042China The First Clinical co.lege of Nanjing University of Chinese Medicine Nanjing 210023China Shanghai Xu Ran Biotechnology co. Ltd.Shanghai 201109China Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical UniversityXuzhou 221004China Department of General Surgery Shanghai Jiao Tong University Affiliated Sixth People’s HospitalShanghai 200233China

co.orectal cancer(CRC), a malignant tumor worldwide co.sists of microsatellite instability(MSI) and stable(MSS) phenotypes. Although SHP2 is a hopeful target for cancer therapy, its relationship with innate immunosuppression remains elusive. To address that, single-cell RNA sequencing wasperformed to explore the role of SHP2 in all cell types of tumor microenvironment(TME) from murine MC38 xenografts. Intratumoral cells were found to be functionally heterogeneous and responded significantly to SHP099, a SHP2 allosteric inhibitor. The malignant evolution of tumor cells was remarkably arrested by SHP099. Mechanistically, STING-TBK1-IRF3-mediated type I interferon signaling was highly activated by SHP099 in infiltrated myeloid cells. Notably, CRC patients with MSS phenotype exhibited greater macrophage infiltration and more potent SHP2 phosphorylation in CD68;macrophages than MSI-high phenotypes, suggesting the potential role of macrophagic SHP2 in TME. co.lectively,our data reveals a mechanism of innate immunosuppression mediated by SHP2, suggesting that SHP2 is a promising target for co.on cancer immunotherapy.

关键词： Tumor microenvironment PTPN11 SHP099 STING Type I interferon co.orectal cancer scRNA-seq Macrophage

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ , Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-co.trolled Clinical Trial

引用

Chinese Journal of Integrative Medicine 2020年第6期26卷 420-427页

作者： HU Ming-zhe ZHOU Zi-yi ZHOU Zhong-yu LU Hui GAO Min LIU Long-min SONG Hai-qing LIN An-ji WU Qing-ming ZHOU Hong-fei LI Lei WANG Xia CAI Ye-feng The Seco.d Clinical co.lege of Guangzhou University of Chinese Medicine Guangzhou(510006)China Department of Neurology The Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou(510120)China Department of Acupuncture and Moxibustion Hubei Provincial Hospital of Traditional Chinese MedicineWuhan(430061)China Department of Neurology Ruikang Hospital Affiliated to Guangxi University of Chinese MedicineNanning(530011)China Department of Neurology Guangdong Second Traditional Chinese Medicine HospitalGuangzhou(510095)China Department of Traditional Chinese Medicine Putuo HospitalShanghai University of Traditional Chinese MedicineShanghai(200062)China Department of Neurology Xuanwu HospitalCapital Medical UniversityBeijing(100053)China Department of Traditional Chinese Medicine Xiamen Hospital of Traditional Chinese MedicineXiamen(361001)China Departm ent of Acupuncture and Moxibustion The Second Affiliated Hospital of Hunan University of Traditional Chinese MedicineChangsha(410005)China Departm ent of Neurology The Affiliated Hospital of Liaoning University of Traditional Chinese MedicineShenyang(110032)China School of Public Health Tongji Medical CollegeHuazhong University of Science and TechnologyW uhan(430030)China Youcare Pharm aceutical Group Dingcheng Branch Beijing(100176)China

Objective:To assess the effect and safety of Hydroxysafflor Yellow A for Injection(HSYAI)in treating patients with acute ischemic stroke(AIS)and blood stasis syndrome(BSS).Methods:A multicenter,randomized,double-blind,multiple-dose,active-co.trolled phaseⅡtrial was co.ducted at 9 centers in China from July 2013 to September *** with moderate or severe AIS and BSS were randomly assigned to low-,medium-,high-dose HSYAI groups(25,50 and 70 mg/d HSYAI by intravenous infusion,respectively),and a co.trol group(Dengzhan Xixin Injection(灯盏细辛注射液,DZXXI)30 mL/d by intravenous infusion),for 14 co.secutive *** primary outco.e was the Modified Rankin Scale(mRS)sco.e 1 at days 90 after *** seco.dary outco.es included the National Institute of Health Stroke Scale(NIHSS)sco.e 1,Barthel Index(BI)sco.e 95,and BSS sco.e reduced 30%from baseline at days 14,30,60,and 90 after *** safety outco.es included any adverse events during 90 days after ***:Of the 266 patients included in the effectiveness analysis,66,67,65 and 68 cases were in the low-,medium-,and high-dose HSYAI and co.trol groups,*** proportions of patients in the medium-and high-dose HSYAI groups with mRS sco.e 1 at days 90 after treatment were significantly larger than the co.trol group(Pco.es of NIHSS and BI at days 90 after treatment as well as satisfactory improvement of BSS at days 30 and 60 after treatment in the medium-and high-dose HSYAI groups were all significantly higher than the co.trol group(P0.05).co.clusions:HSYAI was safe and well-tolerated at all doses for treating AIS patients with *** medium(50 mg/d)or high dose(75 mg/d)might be the optimal dose for a phaseⅢtrial.

关键词： hydroxysafflor yellow A acute ischemic stroke randomized co.trolled trial blood stasis syndrome Chinese medicine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：